Ketoconazole a medicine used for fungal infections is expected to have its license removed due to the risk of fatal hepatotoxicity. This reccomendation has been made by The European Medicines Agency Committee on Medicinal Products for Human Use as the risk of damage to the liver is greater than the benefits of treating fungal infections.

Other oral medicines used to treat fungal infections such as fungal nail infections include terbinafide and itraconazole can also cause damage to the liver and worsen liver disease. Topical ketoconazole is not affected by this decision.

Source: Podiatry Now